BE2014C016I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C016I2
BE2014C016I2 BE2014C016C BE2014C016C BE2014C016I2 BE 2014C016 I2 BE2014C016 I2 BE 2014C016I2 BE 2014C016 C BE2014C016 C BE 2014C016C BE 2014C016 C BE2014C016 C BE 2014C016C BE 2014C016 I2 BE2014C016 I2 BE 2014C016I2
Authority
BE
Belgium
Application number
BE2014C016C
Other languages
French (fr)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BE2014C016I2 publication Critical patent/BE2014C016I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2014C016C 2002-11-15 2014-02-27 BE2014C016I2 (enrdf_load_stackoverflow)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Publications (1)

Publication Number Publication Date
BE2014C016I2 true BE2014C016I2 (enrdf_load_stackoverflow) 2023-03-07

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C016C BE2014C016I2 (enrdf_load_stackoverflow) 2002-11-15 2014-02-27

Country Status (38)

Country Link
EP (2) EP2025338A1 (enrdf_load_stackoverflow)
JP (1) JP4317138B2 (enrdf_load_stackoverflow)
KR (1) KR101092247B1 (enrdf_load_stackoverflow)
CN (3) CN101735166A (enrdf_load_stackoverflow)
AR (2) AR041969A1 (enrdf_load_stackoverflow)
AT (1) ATE430569T1 (enrdf_load_stackoverflow)
AU (1) AU2003285326B2 (enrdf_load_stackoverflow)
BE (1) BE2014C016I2 (enrdf_load_stackoverflow)
BR (1) BRPI0316264B8 (enrdf_load_stackoverflow)
CA (1) CA2506082C (enrdf_load_stackoverflow)
CO (1) CO5570670A2 (enrdf_load_stackoverflow)
CY (2) CY1110500T1 (enrdf_load_stackoverflow)
DE (2) DE10253282A1 (enrdf_load_stackoverflow)
DK (1) DK1562603T3 (enrdf_load_stackoverflow)
EA (1) EA008665B1 (enrdf_load_stackoverflow)
EC (1) ECSP055774A (enrdf_load_stackoverflow)
ES (1) ES2326878T7 (enrdf_load_stackoverflow)
FR (1) FR14C0049I2 (enrdf_load_stackoverflow)
HR (1) HRP20050432B1 (enrdf_load_stackoverflow)
HU (1) HUS1400011I1 (enrdf_load_stackoverflow)
IL (1) IL167900A (enrdf_load_stackoverflow)
LT (1) LTC1562603I2 (enrdf_load_stackoverflow)
LU (1) LU92433I2 (enrdf_load_stackoverflow)
ME (1) ME00354B (enrdf_load_stackoverflow)
MX (1) MXPA05005081A (enrdf_load_stackoverflow)
MY (1) MY136034A (enrdf_load_stackoverflow)
NL (1) NL300650I2 (enrdf_load_stackoverflow)
NO (2) NO334314B1 (enrdf_load_stackoverflow)
NZ (1) NZ540661A (enrdf_load_stackoverflow)
PE (1) PE20040694A1 (enrdf_load_stackoverflow)
PL (1) PL212238B1 (enrdf_load_stackoverflow)
PT (1) PT1562603E (enrdf_load_stackoverflow)
RS (1) RS51607B (enrdf_load_stackoverflow)
SI (1) SI1562603T1 (enrdf_load_stackoverflow)
TW (1) TWI343812B (enrdf_load_stackoverflow)
UA (1) UA81276C2 (enrdf_load_stackoverflow)
WO (1) WO2004045618A2 (enrdf_load_stackoverflow)
ZA (1) ZA200502246B (enrdf_load_stackoverflow)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
NZ550797A (en) * 2004-04-22 2010-08-27 Boehringer Ingelheim Int Pharmaceutical combinations containing 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethylethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one for treating respiratory diseases
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
WO2005110990A1 (de) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
PL1917253T3 (pl) * 2005-08-15 2015-06-30 Boehringer Ingelheim Int Sposób wytwarzania betamimetyków
TWI389692B (zh) * 2005-10-10 2013-03-21 Boehringer Ingelheim Int 用以吸入β-共效劑的氣溶膠調配物
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
WO2007054498A1 (en) * 2005-11-09 2007-05-18 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2642239A1 (en) * 2006-02-16 2007-08-23 Boehringer Ingelheim International Gmbh Drug combinations for the treatment of respiratory tract diseases
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
RU2457209C2 (ru) 2006-04-21 2012-07-27 Новартис Аг Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
US20100222336A1 (en) * 2006-08-07 2010-09-02 Boehringer Ingelheim International Gmbh Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
PL2104535T3 (pl) 2007-01-10 2011-05-31 Irm Llc Związki i kompozycje jako inhibitory proteazy aktywujące kanały
EP2125759B1 (de) * 2007-01-25 2011-08-03 Boehringer Ingelheim International GmbH Verfahren zur herstellung von betamimetika
CN101687851B (zh) 2007-05-07 2013-02-27 诺瓦提斯公司 有机化合物
MY152955A (en) 2007-12-10 2014-12-15 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
BRPI0923862A2 (pt) 2008-12-30 2015-07-28 Pulmagen Therapeutics Inflammation Ltd Compostos sulfonamida para o tratamento de distúrbios respiratórios
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
ES2886022T3 (es) * 2010-09-21 2021-12-16 Intekrin Therapeutics Inc Composiciones farmacéuticas sólidas antidiabéticas
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
AP2013007103A0 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as TRK inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
EP2755967B1 (en) 2011-09-16 2015-10-21 Novartis AG Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
EP3134396B1 (en) 2014-04-24 2019-09-18 Novartis AG Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
WO2018114887A1 (en) 2016-12-20 2018-06-28 Laboratorios Lesvi, S.L. Improved process for the manufacture of r-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
CA3139634A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
WO2021038426A1 (en) 2019-08-28 2021-03-04 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
US11304897B2 (en) 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
EE200200602A (et) * 2000-04-27 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pikatoimelised beetamimeetikumid, meetod nende valmistamiseks ja nende kasutamine ravimitena

Also Published As

Publication number Publication date
CA2506082A1 (en) 2004-06-03
EP1562603B1 (de) 2009-05-06
PE20040694A1 (es) 2004-11-23
LU92433I2 (fr) 2014-06-24
NO2014005I1 (no) 2014-03-10
NO20052883L (no) 2005-06-14
CY2014032I2 (el) 2015-12-09
EP2025338A1 (de) 2009-02-18
JP4317138B2 (ja) 2009-08-19
FR14C0049I2 (fr) 2015-07-24
AR087241A2 (es) 2014-03-12
TW200423943A (en) 2004-11-16
AU2003285326B2 (en) 2009-06-04
FR14C0049I1 (enrdf_load_stackoverflow) 2014-08-08
NL300650I2 (nl) 2017-11-02
NO334314B1 (no) 2014-02-03
ATE430569T1 (de) 2009-05-15
CO5570670A2 (es) 2005-10-31
BRPI0316264B1 (pt) 2019-04-09
BR0316264A (pt) 2005-10-11
PL375270A1 (en) 2005-11-28
JP2006508140A (ja) 2006-03-09
AR041969A1 (es) 2005-06-01
UA81276C2 (en) 2007-12-25
ES2326878T7 (es) 2014-03-11
CN101735166A (zh) 2010-06-16
CA2506082C (en) 2011-06-21
KR20050075013A (ko) 2005-07-19
DK1562603T3 (da) 2009-09-07
WO2004045618A2 (de) 2004-06-03
EA008665B1 (ru) 2007-06-29
TWI343812B (en) 2011-06-21
EP1562603B3 (de) 2014-01-08
IL167900A (en) 2013-06-27
DE10253282A1 (de) 2004-05-27
SI1562603T1 (sl) 2009-10-31
EA200500715A1 (ru) 2005-12-29
PL212238B1 (pl) 2012-08-31
RS20050361A (sr) 2007-04-10
CN101817800A (zh) 2010-09-01
MXPA05005081A (es) 2005-07-01
NZ540661A (en) 2007-12-21
DE50311502D1 (de) 2009-06-18
ZA200502246B (en) 2006-01-25
EP1562603A2 (de) 2005-08-17
ME00354B (me) 2011-10-10
ES2326878T3 (es) 2009-10-21
HRP20050432B1 (en) 2012-01-31
CN1713914A (zh) 2005-12-28
AU2003285326A1 (en) 2004-06-15
MEP53608A (en) 2011-05-10
ECSP055774A (es) 2005-11-22
CY2014032I1 (el) 2015-12-09
HRP20050432A2 (en) 2006-06-30
WO2004045618A3 (de) 2004-09-30
HUS1400011I1 (hu) 2022-02-28
PT1562603E (pt) 2009-06-18
RS51607B (sr) 2011-08-31
LTC1562603I2 (lt) 2016-12-12
MY136034A (en) 2008-07-31
CY1110500T1 (el) 2015-04-29
KR101092247B1 (ko) 2011-12-12
BRPI0316264B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BE2019C547I2 (enrdf_load_stackoverflow)
BE2019C510I2 (enrdf_load_stackoverflow)
BE2018C021I2 (enrdf_load_stackoverflow)
BE2017C049I2 (enrdf_load_stackoverflow)
BE2017C005I2 (enrdf_load_stackoverflow)
BE2016C069I2 (enrdf_load_stackoverflow)
BE2016C040I2 (enrdf_load_stackoverflow)
BE2016C013I2 (enrdf_load_stackoverflow)
BE2015C078I2 (enrdf_load_stackoverflow)
BE2016C002I2 (enrdf_load_stackoverflow)
BE2018C018I2 (enrdf_load_stackoverflow)
BE2015C017I2 (enrdf_load_stackoverflow)
BE2014C053I2 (enrdf_load_stackoverflow)
BE2014C051I2 (enrdf_load_stackoverflow)
BE2014C041I2 (enrdf_load_stackoverflow)
BE2014C030I2 (enrdf_load_stackoverflow)
BE2014C015I2 (enrdf_load_stackoverflow)
BE2013C063I2 (enrdf_load_stackoverflow)
BE2013C039I2 (enrdf_load_stackoverflow)
BE2011C038I2 (enrdf_load_stackoverflow)
JP2003122509A5 (enrdf_load_stackoverflow)
JP2003116134A5 (enrdf_load_stackoverflow)
BE2015C069I2 (enrdf_load_stackoverflow)
BE2013C046I2 (enrdf_load_stackoverflow)
JP2002273889A5 (enrdf_load_stackoverflow)